The Study of CM326 in Adult Subjects With Atopic Dermatitis
NCT ID: NCT05671445
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2023-02-09
2025-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
NCT05671432
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
NCT05186922
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT05265923
A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT06116565
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis
NCT06162507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM326
CM326 injection, subcutaneous (SC)
CM326
CM326 injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM326
CM326 injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have the ability to understand the nature of the study and voluntarily sign the informed consent.
* Be able to communicate well with investigators and follow up protocol requirements.
* The subjects agreed to use highly effective contraceptive measures during the study.
Exclusion Criteria
* Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.
* Major surgery is planned during the study period.
* Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianzhong Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM326-101105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.